Compare LU & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LU | OGN |
|---|---|---|
| Founded | 2005 | 1923 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 2020 | 2020 |
| Metric | LU | OGN |
|---|---|---|
| Price | $1.42 | $13.52 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 5 |
| Target Price | $2.00 | ★ $11.40 |
| AVG Volume (30 Days) | 1.5M | ★ 2.3M |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 0.60% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.55 |
| Revenue | N/A | ★ $6,216,000,000.00 |
| Revenue This Year | N/A | $0.45 |
| Revenue Next Year | $22.52 | $1.67 |
| P/E Ratio | ★ N/A | $24.64 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.20 | $5.69 |
| 52 Week High | $4.57 | $13.60 |
| Indicator | LU | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 48.55 | 68.64 |
| Support Level | $1.29 | $10.05 |
| Resistance Level | $2.77 | N/A |
| Average True Range (ATR) | 0.07 | 0.06 |
| MACD | 0.03 | -0.05 |
| Stochastic Oscillator | 89.80 | 59.52 |
Lufax Holding Ltd is an investment holding company, together with its consolidated subsidiaries, engaged in core retail credit and enablement business to both borrowers and institutions in the People's Republic of China. The group's segments are Lending-related business, which provides Retail credit and enablement, consumer finance loans, and Digital banking business, including Retail banking and SME banking.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.